drugset / Trial / NCT02137837
S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer
RandomizedParallel-groupTriple-blindTreatment
Summary
This randomized Phase III trial studies how well the combination of fulvestrant and everolimus together or the combination of anastrozole, fulvestrant and everolimus together, improve progression-free survival (PFS) versus fulvestrant alone.
Timeline
- Start
- 2014-05
- Primary completion
- 2019-12-31
- Completion
- 2019-12-31
Outcome
Outcome not reported
Stopped (Enrollment): “lack of accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anastrozole | Other / unclassified | — | Oral |
| Subject | Everolimus | Small molecule | — | Oral |
| Subject | Fulvestrant | Small molecule | — | Other |